Regression of Cervical Precancerous Lesions and Associated Risk Factors

Launched by GENERAL UNIVERSITY HOSPITAL, PRAGUE · Nov 24, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well severe precancerous changes in the cervix, known as CIN 2 and CIN 3, can improve or go away after treatment. Researchers want to see how many women treated with two different methods—conservative management or a procedure called conization—show improvement in both their HPV tests and cervical cell results. They also aim to find out what factors might help predict whether these changes will get better.

To participate in the trial, women must be between the ages of 18 and 40, have a confirmed diagnosis of CIN 2 or CIN 3, and be able to provide informed consent. Unfortunately, women who have had certain medical conditions, such as a history of cervical cancer or those who are immunocompromised, cannot participate. If you join the study, you can expect to be monitored closely for changes in your condition and may contribute to important research that could help others in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. squamocolumnar junction fully visualized
• • 2. bioptically verified CIN 2 or CIN 3
• • 3. age ≥ 18 years
• • 4. age ≤ 40 years
• • 5. informed consent
• Exclusion Criteria:
• • 1. squamocolumnar junction not fully visualized
• • 2. suspicion on glandular lesion
• • 3. suspicion on invasive cancer
• • 4. personal history of CIN 2, 3 or cerv. cancer
• • 5. gravidity
• • 6. HIV positivity
• • 7. immunosuppression
• • 8. impossible photographic documentation